OncoMatch/Clinical Trials/NCT06912763
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
Is NCT06912763 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for fibrosis syndrome.
Treatment: Pravastatin (drug) · Pentoxifylline · ketoprofen · Pirfenidoneone · tocopherol — To find out if adding medication can help treat or prevent lymphedema and/or fibrosis related to radiation therapy, in survivors of head and neck cancer. Researchers will compare these drugs to find the most effective therapy for preventing or limiting these side effects.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: radiation therapy
Treated previously with radiotherapy with prescribed dose (greater or equal to 30Gy) to unilateral or bilateral neck(s)
Lab requirements
Kidney function
Creatinine clearance <30mL/min
Liver function
No active liver disease (Child-Pugh class B-C), cirrhosis, nor active alcoholism
Cardiac function
No history of acute myocardial infarction or severe coronary disease
No active liver disease (Child-Pugh class B-C), cirrhosis, nor active alcoholism, nor history of ulcers. Creatinine clearance <30mL/min. No history of acute myocardial infarction or severe coronary disease.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify